Clinical trials: Carcinosarcoma
Bone Sarcoma, Dedifferentiated Chondrosarcoma
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer…
- Conditions
- Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone
- Trial name
- NCT03449108
- Testing
- Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
This phase II clinical trial studies the side effects and how well imatinib mesylate works in treating patients with uterine cancer that has failed to respond to initial chemotherapy or has re-grown after therapy.
- Trial name
- NCT00075400
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin), Basal Cell Carcinoma
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
The purpose of this clinical study is to evaluate if the DermaSense prototype EIS scanner can provide medical decision support which can complement dermoscopy-based identification of the disease at time of biopsy decision.
- Conditions
- Melanoma (Skin), Basal Cell Carcinoma, Squamous Cell Carcinoma, Dysplastic Nevus Syndrome
- Trial name
- DermaSense (NCT04688749)
- Testing
- Electrical Impedence Spectroscopy DermaSense
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Mixed Tumor, Mullerian
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.
- Trial name
- NCT00502203
- Testing
- Carboplatin, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent or…
- Trial name
- NCT00003156
- Testing
- topotecan hydrochloride
- Where
- 46 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Endometrial Cancer, Gastrointestinal Stromal Tumor
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective treatment for soft tissue sarcoma. PURPOSE: Phase I/II trial to study the effectiveness of STI571 in treating patients who have recurrent or…
- Conditions
- Endometrial Cancer, Gastrointestinal Stromal Tumor, Ovarian Cancer, Sarcoma
- Trial name
- NCT00006357
- Testing
- imatinib mesylate
- Where
- 16 sites in Belgium, Denmark and 3 more
- Volunteers
- 91 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Endometrial Cancer, Sarcoma
Thalidomide in Treating Patients With Gynecologic Sarcomas
RATIONALE: Thalidomide may stop the growth of gynecologic sarcomas by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent…
- Trial name
- NCT00006005
- Testing
- thalidomide
- Where
- 10 sites in United States
- Sponsor
- New York University Cancer Institute
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Endometrial Cancer, Fallopian Tube Cancer
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003334
- Testing
- paclitaxel, pegylated liposomal doxorubicin hydrochloride
- Where
- 5 sites in United States
- Sponsor
- NYU Langone Health
Endometrial Cancer, Kidney Cancer
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in…
- Conditions
- Endometrial Cancer, Kidney Cancer, Ovarian Cancer, Pheochromocytoma
- Trial name
- NCT00002641
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 45 sites in Austria, Belgium and 11 more
- Volunteers
- 350 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite…
- Trial name
- NCT00025506
- Testing
- Laboratory Biomarker Analysis, Thalidomide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer
- Trial name
- SAVE (NCT03422198)
- Testing
- Vaginal Cuff Brachytherapy, Short course vaginal cuff brachytherapy
- Where
- 5 sites in United States
- Volunteers
- 188 people
- Sponsor
- University of Utah
Endometrial Cancer, Sarcoma
Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether receiving radiation therapy or no further therapy after surgery is more effective for cancer of the uterus.
- Trial name
- NCT00002459
- Testing
- radiation therapy
- Where
- 28 sites in Belgium, Canada and 8 more
- Volunteers
- 224 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Uterine Neoplasms
Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
Primary Objectives: 1. To test whether the addition of chemotherapy to radiotherapy improves the progression-free survival for patients with stage I, II and IIIa malignant mixed mesodermal tumor (MMMT) of the uterus. 2.
- Trial name
- NCT00505492
- Testing
- Carboplatin, Cisplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with recurrent or persistent uterine cancer.
- Trial name
- NCT00114218
- Testing
- Gemcitabine Hydrochloride, Docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Gynecologic Oncology Group
Carcinosarcoma, Endometrial Neoplasms
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
The COPELIA trial is evaluating two new tablet medications in endometrial cancer for the first time. It will include 129 women aged 16 years or older with advanced endometrial cancer whose cancer has worsened after their initial…
- Trial name
- COPELIA (NCT03570437)
- Testing
- Paclitaxel, Cediranib, Olaparib
- Where
- 15 sites in United Kingdom
- Volunteers
- 124 people
- Sponsor
- University of Manchester
Ovarian Cancer, High Grade Serous Carcinoma
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
In BriTROC-2, up to 250 women with a confirmed diagnosis of high-grade serous/high-grade endometrioid or carcinosarcoma will be eligible for full consent (Part 2) and registration to BriTROC-2 and will be followed prospectively…
- Conditions
- Ovarian Cancer, High Grade Serous Carcinoma, Carcinosarcoma, Ovarian, Fallopian Tube Cancer
- Trial name
- BriTROC-2 (NCT05537844)
- Where
- 11 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- Liz-Anne Lewsley